Thursday, May 10, 2007

New Pharma Blog Planet Discovered!

This observer of the Pharma BlogosphereTM wishes to register this new sighting among the "Outer Sphere" of influence: Prescription Access Litigation (PAL to their friends) Blog!

Launched just today, and not yet formally announced, here's PAL Blog's opening statement:

This blog will feature updates on activities of Prescription Access Litigation (PAL) and its members, including class action lawsuits, amicus curiae (Friend of the Court”) briefs, regulatory and legislative testimony and public education campaigns. We will also feature commentary on major developments and news stories on the pharmaceutical industry.

The PAL blog will not be updated daily, but rather as we have news to report. There are a number of daily pharmaceutical blogs that do a great job of covering the industry every day. See our blogroll on the left.

The universe of pharmaceutical blogs has grown rapidly over the past few months, as ably documented by John Mack over at PharmaBlogosphere. Some of its luminaries include industry critics and gadflies, such as Peter Rost and the pseudonymous Jack Friday (aka “Insider”). But as far as we have been able to ascertain, there are no other blogs critical of the industry that are written strictly from a consumer perspective. We hope to help partially fill that void.

So tune in, and stay tuned… We welcome your comments and suggestions.

I hope that PAL Blog does take a strictly consumer-centric viewpoint and does not just report on PAL litigation issues, which might wear thin after awhile. Anyway, that's my advice.

BTW, PAL Director and blogger Alex Sugerman-Brozan, was a guest not too long ago on a Pharma Marketing Talk podcast dedicated to disease mongering. Access and listen to the audio archive here.


More Dirt on the Co-optation of Rx Daily Dose Blog by Pfizer

Earlier today, we learned that Rx Daily Dose blogger and Boston Herald op-ed columnist Virginia Buckingham rocketed out of the Pharma BlogosphereTM and landed a job as a Pfizer lobbyist (see "Is a Pharma PR Job In Your Future?"). i picked this up from PharmaGossip.

Ed Silverman over at Pharmalot picked up and added to the story:

"Until recently, Ginny [Ed and Ms. Buckingham must be buddies if he can get away with using this familiar form of her name] also managed the content of Rx Daily Dose, a blog that may be familiar to some of you. This is how the blog describes itself: 'On a daily basis, RxDailyDose will correct the record, expose the biases and clarify the cost to patients of misguided policies, off-base attacks and hypocritical politicians targeting an industry whose constant discovery of new and better medicines has improved health and extended lives.'

"Not sure if the blog exists anymore [Nope, it doesn't. Seriously, Ed you got to visit here more frequently. It doesn't look good for a journalist to admit to not knowing something!]. But it was begun as a project of the Institute For Liberty, a conservative group. The organization's president, Jason Wright, was previously a vp at Frontiers of Freedom Institute, another conservative group that was founded by Malcolm Wallop, a former republican senator from Wyoming. His group receives backing from oil and tobacco companies, according to SourceWatch."
This is the closest connection I can find between the drug, oil, and tobacco industries, other than they all are way down in the cellar of public opinion ... THEY HIRE MOUTHPIECES FROM THE SAME REPUBLICAN THINK TANKS! How cozy!

Is a Pharma PR Job In Your Future?

First, pharmaceutical companies invite "prominent" bloggers to the dinner table for an "informal get-together" (see "Should Bloggers Dine at Pharma's Table?"). Then, they start hiring bloggers!

According to a post by "Insider" Jack Friday on PharmaGossip:

Rx Daily Dose blogger joins Pfizer

Rx Daily Dose blogger and Boston Herald op-ed columnist Virginia Buckingham is to to work for drugmaker Pfizer as a lobbyist focusing on New England.

The blog has already been consigned to history!

She served as deputy editorial page editor of the Herald from January 2003 to July 2005 when she began writing a regular column, which focused mainly on state and national politics.

As assistant director of government relations, Buckingham will work for New York-based Pfizer’s Worldwide Public Affairs and Policy Division.

Insider wishes Virginia all the best.

When you sup with the devil, use a long spoon!

Maybe Pfizer first invited Virginia to dinner and was so impressed that it hired her. Or maybe it was posts like this (sorry, I only have the feed summary; the blog, as Jack notes, is gone):
"Enormous" Pharma's challenge
Pfizer CEO Jeff Kindler likens it to "changing the tires on a moving vehicle." This insightful article in The Economist is the most comprehensive look at the coming transformation of pharma's business model I've seen anywhere. From "personalized medicine" to the $1 billion pill to the rise of "drug hunters", there's a mountain the size of Everest to climb to overcome all the obstacles. But nothing is more important to healthy lives than a healthy drug industry.

Question: What will the government do to help, not hurt?
A little sympathy goes a long way! Maybe that's why I didn't get the job after turning Kindler's remarks into an April Fool's joke (see "Kindler's Refreshing View of Pharma's Problems and His Job").

I wonder if any of the guys meeting with J&J at that recent dinner party have been approached about employment in J&J's PR department -- especially those journalist, PR, and physician bloggers that attended?

Inquiring minds want to know!

Wednesday, May 9, 2007

Stats: I'll Show You Mine; Will You Show Me Yours?

The mission of Pharma BlogosphereTM, believe it or not, is to promote the rising luminaries of our little sphere of influence. By writing about and linking to blogs in this sphere, I believe I have helped bring attention to our little world and increase the number of readers for each and every one of us.

I think I have some evidence to back that statement. The evidence resides in site statistics; namely number of visitors and page views.

This is a very touchy subject because often metrics are a closely-held asset, especially that "etc." stuff (IP addresses of site visitors, referring pages, etc.). As far as personally-identifiable metrics like IP addresses, a few bloggers -- notably Peter Rost -- are open about their privacy policies. Others, myself included, have not gotten around to making those policies public. It's not that we are hiding anything, we've just been lazy or, more likely, blogging is so new that we've never thought about some of these things. A few of us don't even collect the sort of information for which policies are necessary. So don't take this as a personal condemnation. Just a wake up call.

But I really want to talk about de-identified or aggregate visitor data, specifically number of visitors and page views.

Bloggers use a number of different applications to measure these metrics, which means there is no clear standard and it is not possible to compare one blog's metrics with another's; no statistically accurate way, that is. So, anything I say here is not meant to accurately compare one blog with another (despite the provocative title of this post, which was meant to grab your attention more than to challenge you).

Rather, I'd like to reveal some metrics in the realm of pharma blogging to see how we compare to other blogging topic areas, or to measure our progress over time. I have had a few people ask me if the numbers they are getting are average for a blog in this sphere or maybe above or below average. Of course, I have no way of knowing, but by revealing what I know about my blog (Pharma Marketing Blog) and what's public from other blogs in this sphere, I hope newbies can better measure their progress and popularity.

I will look at the metrics of three different blogs in the Pharma Blogosphere: Pharma Marketing Blog, The Health Care Blog (THCB) and Eye On FDA.

Visitors
Mark Senak at Eye On FDA uses a service called eXTReMe Tracking. From what I can see by clicking on the stats logo on the blog, Eye On FDA averages 3,228 unique visitors per month, or 5,412 visitors in April, which compares to THCB's 30,000 and Pharma Marketing Blog's 18,000 unique visits per month.

The latter two blogs use Site Meter, which defines a "visit" as a series of page views by one person with no more than 30 minutes in between page views. I am not sure how eXTReMe defines unique visitor and how this relates to Site Meter's unique visits.

Page Views
Last month (April 2007), THCB logged approximately 52,000 page views, whereas Pharma Marketing Blog logged about 31,000 page views. I can't figure out how to get Eye on FDA page view data from the publicly available stats link provided.

I have always compared my stats to THCB's stats because this is a great blog in a field much larger than pharmaceutical marketing, which is what I focus on. Last year, I was happy that Pharma Marketing Blog registered one-third (33%) the number of visitors that THCB was getting at the time. Today, that figure is closer to 60%!

I attribute this to the phenomenon of "a rising tide floats all ships" -- that is, as the number of bloggers in the Pharma Blogosphere sea has increased, and as we link to one another and get tracked by other sites like Cafe Pharma and PharmaCentral PageFlakes, that sea level will continue to rise and float all of us even higher! At least I hope so.

Stats For Pharma Marketing Blog
Let's get back to the evidence. The following chart was captured directly from the Site Meter stats page for Pharma Marketing Blog. It shows visits (yellow) and page views (red) per month for the last 12 months. The arrow indicates when I started the Pharma Blogosphere blog. Looks like the rising tide floated my boat! Did it float yours too?

# of Posts
But rising visitor stats is not just due to the fact that more attention is being paid these days to pharma bloggers. I have also made more posts per month than I did last year as the following chart shows.


I now average about 21 posts per month, which is more than many other pharma blogs but much less than others, especially Pharmalot, PharmaGossip, etc. However, my postings tend to be lengthier and more in-depth than others -- I average about 800 words per post! At that rate, I estimate that I am writing over 200,000 words per year or over 300 pages! That's a book!

# of Comments
One of the distinguishing feature of blogging is the comments that people can make and thereby participate in the discussion. That discussion is very important to me. I learn from other people's comments and that helps me create a more useful blog and newsletter for my subscribers.

Between January and April of this year, I have received approximately 3,200 comments. That's about 2-3 comments per post! Perhaps not a lot by general blog standards, but pretty good for this small sphere of influence.

OK, I've showed you my stats and I used a verifiable 3rd-party chart or data that anyone can collect from my blog. So, no smoke and mirrors. I'd be interested in learning how other blogs in this space are doing stat-wise.

Inquiring minds want to know.